HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 24, No. 09, September 2020 – 3D Technology: Additive Manufacturing Applications and Prospects       » Results of CD30 CAR-T Cell Therapy Trial Shows Promise for Hodgkin Lymphoma Patients       » Emerging Technologies and Innovations amid a Global Pandemic       » Monitoring COVID-19 Patients with AI-powered Platform       » Singapore Researchers Devise a Rapid COVID-19 Test Kit for the Detection of Neutralising Antibodies (NAbs) Against SARS-CoV-2       » Novel Ventilator Conceptualized by Singapore Clinicians Provides Efficient and Personalized Breathing Support for COVID-19 patients      
Vol 24, No. 09, September 2020   |   Issue PDF view/purchase
EYE ON CHINA
Key Insights to the World’s Second-Largest Healthcare Market
Findings from a healthcare report on China by the South China Morning Post (SCMP) revealed the latest trends in healthtech innovation, biopharmaceuticals, healthcare manufacturing, and COVID-19 vaccines.

Healthcare industry in China currently a leader in the world with double-digit growth. Its domestic healthcare market also has a large impact on the global healthcare market as the second largest healthcare market by an expenditure of USD 3.5 trillion in 2018. The report released by SCMP in August 2020 also followed the impact of COVID-19 on the structural shifts in the global supply chain for healthcare products. It also included an overview of COVID-19 vaccine developments together with leading healthcare innovators and industry leaders in China.

Using case studies, the report gave an in-dept overview of the latest developments in the business of China’s healthcare industry, it covered the opportunities, risks, and predictions for the industry. Created by SCMP Research, it takes advantage of SCMP’s wide reach in China to cover major sectors such as pharmaceuticals, biotechnology, medical devices and supplies manufacturing, service providers, and healthcare technology.

There were several key findings from the report, most of which highlight the current state of the various sectors of China’s healthcare industry as well as projections for the future, taking into account the recent COVID-19 pandemic.

First, the report showed the growth in massive investment in research and development as well as innovation. With a staggering forecasted growth of 23 percent compound annual rate until 2023, China’s combined pharmaceutical and biopharmaceutical R&D spending will reach USD 49 million. This will make up 23 percent of global spending on drug discovery and testing.

Biopharmaceutical sales also saw a rapid growth in China, which has doubled since 2016 and are projected to reach almost USD 50 million by 2021.

Supplies for medical devices and equipment from China accounted for USD 10 billion make up to 2.6 percent of total exports in first quarter of 2020. The Chinese government’s Made in China 2025 strategic plan pushes for increased concentration on innovation to bring manufacturing up the value chain for high-tech medical devices.

China manufactures 40 percent of APIs (Active Pharmaceutical Ingredients) used worldwide and is a leading supplier of basic chemicals to the global pharmaceutical industry, worth 384.3 billion yuan (USD 54 billion) in 2018. This shows the dominance of China in the global export of APIs.

Recent COVID-19 global pandemic prompted an increase in diagnoses and rise in prescription through online healthcare platforms. As one of the first few epicentres for the outbreak, health technology in China has taken the fast lane in adoption of accelerated alternatives to tradition processes in the healthcare industry. Artificial intelligence (AI) in CT scans, algorithms for COVID-19 detection in genomic sequencing, and AI-based research platforms for vaccines are just some of them.

SCMP’s Executive Editor Chow Chung-yan said, “The world is facing an acute healthcare challenge when people are living much longer, populations are rapidly ageing, and healthcare costs are rising. China aims to significantly improve its healthcare standards to be on par with those in developed nations by 2030. This will spur innovation in the sector, provide impetus for growth in the global healthcare industry, and catapult Chinese healthcare firms onto the international stage.”

Through this report SCMP hoped to target those interested to understand the complexity of China’s healthcare market and how it will impact global markets, these include academics, investors and key stakeholders.

 

NEWS CRUNCH  
news PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season
news PharmaSources.com to Help Propel the Chinese API Export Business with E-Trade Session CPhI China Top API Exporters & Products
news Singapore Biomedical Company Appointed as a Certified Service Provider by 10x Genomics
news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy